Crossmark

Screening for genetic mutations in patients with neuropathy without definite etiology is useful

Published Online: 2020-05-12

Published Print: 2020-09

Authors

Vogt, Braden

Chahin, Nizar

Wiszniewski, Wojciech

Ragole, Thomas

Karam, Chafic
License Information

Text and Data Mining valid from 2020-05-12

Version of Record valid from 2020-05-12
More Information

Article History

Received: 26 March 2020

Revised: 4 May 2020

Accepted: 6 May 2020

First Online: 12 May 2020

Compliance with ethical standards

:

: Braden Vogt reports no disclosures. Nizar Chahin has served on advisory boards for Sarepta. Wojciech Wiszniewski reports no disclosures. Thomas Ragole has received honoraria for consulting with L.E.K. Consulting. Chafic Karam has served on advisory boards for Acceleron, Akcea, Alexion, Alnylam, Argenx, Biogen, CSL Behring, Cytokinetics and Sanofi-Genzyme, and received research grants from Genzyme and Akcea.

: This study was approved by the Oregon Health and Science University IRB.

: OHSU IRB approved this study and patient consent was not required for this retrospective chart review.

: All authors consent to the publication of this manuscript.

Document is current